Hot Flash Therapies in Breast Cancer Survivors
More than 86% of those diagnosed with invasive breast cancer are expected to survive for ≥ 5 years after their diagnosis. Approximately 75% of postmenopausal women who had breast cancer report experiencing hot flashes. More than 90% of young survivors also experience hot flashes, which can be more s...
Gespeichert in:
| Veröffentlicht in: | Supportive cancer therapy 2006-10, Vol.4 (1), p.38-48 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 48 |
|---|---|
| container_issue | 1 |
| container_start_page | 38 |
| container_title | Supportive cancer therapy |
| container_volume | 4 |
| creator | Chang, Yuan-Ching Parker, Jeanene Dooley, William C. |
| description | More than 86% of those diagnosed with invasive breast cancer are expected to survive for ≥ 5 years after their diagnosis. Approximately 75% of postmenopausal women who had breast cancer report experiencing hot flashes. More than 90% of young survivors also experience hot flashes, which can be more severe and long lasting, with iatrogenic ovarian ablation or antiestrogen therapy. There are numerous options for the treatment of hot flashes. Not one treatment fits all. Some treatments are generally more effective than others, and each has different side effects. This review is meant to provide the basic information needed to make a decision about the best treatment for a breast survivor experiencing hot flashes. |
| doi_str_mv | 10.3816/SCT.2006.n.030 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733666298</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S154329121360017X</els_id><sourcerecordid>733666298</sourcerecordid><originalsourceid>FETCH-LOGICAL-c258t-545578f53cf32e4e32397f63f672dec3a1c74b532a5c29bb37097da499abcefb3</originalsourceid><addsrcrecordid>eNp1kDFPwzAQhS0EoqWwMqJsTAm2L3biESJKkSoxtMyW41xUozQpdlqJf4-rVmJiujd870n3EXLPaAYlk0-rap1xSmXWZxToBZkylUMKoMRlzCJmrhifkJsQvijlElh5TSaslMBzKaYkWwxjMu9M2CTrDXqzcxgS1ycvHk0Yk8r0Fn2y2vuDOww-3JKr1nQB7853Rj7nr-tqkS4_3t6r52VquSjHVORCFGUrwLbAMUfgoIpWQisL3qAFw2yR1wK4EZaruoaCqqIxuVKmttjWMCOPp92dH773GEa9dcFi15keh33QBYCUkqsyktmJtH4IwWOrd95tjf_RjOqjIh0V6aMi3euoKBYeztP7eovNH352EoHyBGB88ODQ62AdRg-N82hH3Qzuv-1f3x1zSw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733666298</pqid></control><display><type>article</type><title>Hot Flash Therapies in Breast Cancer Survivors</title><source>Alma/SFX Local Collection</source><creator>Chang, Yuan-Ching ; Parker, Jeanene ; Dooley, William C.</creator><creatorcontrib>Chang, Yuan-Ching ; Parker, Jeanene ; Dooley, William C.</creatorcontrib><description>More than 86% of those diagnosed with invasive breast cancer are expected to survive for ≥ 5 years after their diagnosis. Approximately 75% of postmenopausal women who had breast cancer report experiencing hot flashes. More than 90% of young survivors also experience hot flashes, which can be more severe and long lasting, with iatrogenic ovarian ablation or antiestrogen therapy. There are numerous options for the treatment of hot flashes. Not one treatment fits all. Some treatments are generally more effective than others, and each has different side effects. This review is meant to provide the basic information needed to make a decision about the best treatment for a breast survivor experiencing hot flashes.</description><identifier>ISSN: 1543-2912</identifier><identifier>EISSN: 1943-3395</identifier><identifier>DOI: 10.3816/SCT.2006.n.030</identifier><identifier>PMID: 18632465</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Antidepressants ; Belladonna ; Clonidine ; Gabapentin ; Hormonal therapy ; Methyldopa ; Nonhormonal therapy</subject><ispartof>Supportive cancer therapy, 2006-10, Vol.4 (1), p.38-48</ispartof><rights>2006 Elsevier</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c258t-545578f53cf32e4e32397f63f672dec3a1c74b532a5c29bb37097da499abcefb3</citedby><cites>FETCH-LOGICAL-c258t-545578f53cf32e4e32397f63f672dec3a1c74b532a5c29bb37097da499abcefb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18632465$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chang, Yuan-Ching</creatorcontrib><creatorcontrib>Parker, Jeanene</creatorcontrib><creatorcontrib>Dooley, William C.</creatorcontrib><title>Hot Flash Therapies in Breast Cancer Survivors</title><title>Supportive cancer therapy</title><addtitle>Support Cancer Ther</addtitle><description>More than 86% of those diagnosed with invasive breast cancer are expected to survive for ≥ 5 years after their diagnosis. Approximately 75% of postmenopausal women who had breast cancer report experiencing hot flashes. More than 90% of young survivors also experience hot flashes, which can be more severe and long lasting, with iatrogenic ovarian ablation or antiestrogen therapy. There are numerous options for the treatment of hot flashes. Not one treatment fits all. Some treatments are generally more effective than others, and each has different side effects. This review is meant to provide the basic information needed to make a decision about the best treatment for a breast survivor experiencing hot flashes.</description><subject>Antidepressants</subject><subject>Belladonna</subject><subject>Clonidine</subject><subject>Gabapentin</subject><subject>Hormonal therapy</subject><subject>Methyldopa</subject><subject>Nonhormonal therapy</subject><issn>1543-2912</issn><issn>1943-3395</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNp1kDFPwzAQhS0EoqWwMqJsTAm2L3biESJKkSoxtMyW41xUozQpdlqJf4-rVmJiujd870n3EXLPaAYlk0-rap1xSmXWZxToBZkylUMKoMRlzCJmrhifkJsQvijlElh5TSaslMBzKaYkWwxjMu9M2CTrDXqzcxgS1ycvHk0Yk8r0Fn2y2vuDOww-3JKr1nQB7853Rj7nr-tqkS4_3t6r52VquSjHVORCFGUrwLbAMUfgoIpWQisL3qAFw2yR1wK4EZaruoaCqqIxuVKmttjWMCOPp92dH773GEa9dcFi15keh33QBYCUkqsyktmJtH4IwWOrd95tjf_RjOqjIh0V6aMi3euoKBYeztP7eovNH352EoHyBGB88ODQ62AdRg-N82hH3Qzuv-1f3x1zSw</recordid><startdate>20061001</startdate><enddate>20061001</enddate><creator>Chang, Yuan-Ching</creator><creator>Parker, Jeanene</creator><creator>Dooley, William C.</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20061001</creationdate><title>Hot Flash Therapies in Breast Cancer Survivors</title><author>Chang, Yuan-Ching ; Parker, Jeanene ; Dooley, William C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c258t-545578f53cf32e4e32397f63f672dec3a1c74b532a5c29bb37097da499abcefb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Antidepressants</topic><topic>Belladonna</topic><topic>Clonidine</topic><topic>Gabapentin</topic><topic>Hormonal therapy</topic><topic>Methyldopa</topic><topic>Nonhormonal therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chang, Yuan-Ching</creatorcontrib><creatorcontrib>Parker, Jeanene</creatorcontrib><creatorcontrib>Dooley, William C.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Supportive cancer therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chang, Yuan-Ching</au><au>Parker, Jeanene</au><au>Dooley, William C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hot Flash Therapies in Breast Cancer Survivors</atitle><jtitle>Supportive cancer therapy</jtitle><addtitle>Support Cancer Ther</addtitle><date>2006-10-01</date><risdate>2006</risdate><volume>4</volume><issue>1</issue><spage>38</spage><epage>48</epage><pages>38-48</pages><issn>1543-2912</issn><eissn>1943-3395</eissn><abstract>More than 86% of those diagnosed with invasive breast cancer are expected to survive for ≥ 5 years after their diagnosis. Approximately 75% of postmenopausal women who had breast cancer report experiencing hot flashes. More than 90% of young survivors also experience hot flashes, which can be more severe and long lasting, with iatrogenic ovarian ablation or antiestrogen therapy. There are numerous options for the treatment of hot flashes. Not one treatment fits all. Some treatments are generally more effective than others, and each has different side effects. This review is meant to provide the basic information needed to make a decision about the best treatment for a breast survivor experiencing hot flashes.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>18632465</pmid><doi>10.3816/SCT.2006.n.030</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1543-2912 |
| ispartof | Supportive cancer therapy, 2006-10, Vol.4 (1), p.38-48 |
| issn | 1543-2912 1943-3395 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733666298 |
| source | Alma/SFX Local Collection |
| subjects | Antidepressants Belladonna Clonidine Gabapentin Hormonal therapy Methyldopa Nonhormonal therapy |
| title | Hot Flash Therapies in Breast Cancer Survivors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T02%3A16%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hot%20Flash%20Therapies%20in%20Breast%20Cancer%20Survivors&rft.jtitle=Supportive%20cancer%20therapy&rft.au=Chang,%20Yuan-Ching&rft.date=2006-10-01&rft.volume=4&rft.issue=1&rft.spage=38&rft.epage=48&rft.pages=38-48&rft.issn=1543-2912&rft.eissn=1943-3395&rft_id=info:doi/10.3816/SCT.2006.n.030&rft_dat=%3Cproquest_cross%3E733666298%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733666298&rft_id=info:pmid/18632465&rft_els_id=S154329121360017X&rfr_iscdi=true |